TY  - JOUR
AU  - Meca-Lallana, Virginia
AU  - García Domínguez, José M
AU  - López Ruiz, Rocío
AU  - Martín-Martínez, Jesús
AU  - Arés Luque, Adrián
AU  - Hernández Pérez, Miguel A
AU  - Prieto González, José M
AU  - Landete Pascual, Lamberto
AU  - Sastre-Garriga, Jaume
PY  - 2022
DO  - 10.1007/s40120-022-00394-0
SN  - 2193-8253
UR  - http://hdl.handle.net/10668/21508
T2  - Neurology and therapy
AB  - Cladribine is a disease-modifying selective immune reconstitution oral therapy for adult patients with highly active relapsing multiple sclerosis (RMS). It was approved in the USA in 2019 and in Europe in 2017, thus there are still gaps in existing...
LA  - en
KW  - Cladribine
KW  - Consensus
KW  - Disease-modifying drugs
KW  - Expert opinion
KW  - Relapsing multiple sclerosis
KW  - Treatment response
TI  - Expert-Agreed Practical Recommendations on the Use of Cladribine.
TY  - research article
VL  - 11
ER  -